CXCR4 and pancreatic ductal adenocarcinoma: The analysis of the data from the phase IIa study (NCT02826486) suggests that a combination of PD-1 blockade and CXCR4 antagonist can lead to an improvement in pancreatic ductal adenocarcinoma survival [68].